Allergies are not just seasonal discomfort they are linked to major outcomes, including 4.3% of global deaths attributable to asthma. Even in the U.S., the picture is sharply split between everyday prevalence like about 10% hay fever and fast growing markets such as the global allergies market projected to hit $40.9 billion in 2025. This post connects those clinical realities with the data behind testing, immunotherapy, biologics, and the true cost of allergic disease from emergency visits to disability days.
Key Takeaways
- 4.3% of deaths globally are attributable to asthma
- The prevalence of hay fever (allergic rhinitis) in the United States is about 10%
- Global allergic rhinitis prevalence is estimated at 10%–30% of the population
- In the U.S., asthma prevalence was 8.6% among adults in 2023
- In the U.S., 3.5 million people have asthma who are children
- Component-resolved diagnostics uptake is increasing in allergy clinics because it can improve specificity of allergen sensitization interpretation
- Global allergies market is expected to reach $40.9 billion in 2025
- The global allergy immunology therapeutics market is forecast to grow at a CAGR of 5.7% from 2023 to 2030
- The U.S. allergy testing market is projected to reach $1.8 billion by 2030
- Serum-specific IgE testing can detect sensitization to specific allergens within minutes to days, depending on lab workflow
- Nasal provocation testing is used to confirm allergic rhinitis triggers in clinical research protocols
- Fractional exhaled nitric oxide (FeNO) testing is used as a non-invasive marker of eosinophilic airway inflammation, aiding asthma management decisions
- Economic burden of allergic disorders is linked to comorbid asthma and chronic rhinitis, increasing total healthcare utilization
- Anaphylaxis incidence and emergency utilization drive direct medical costs in emergency care settings
- Globally, allergic rhinitis causes substantial indirect costs through lost productivity, with billions in annual economic burden reported in reviews
Asthma and allergic rhinitis affect millions worldwide, driving major health and economic burdens.
Related reading
01 · Category
Epidemiology9 stats
01
4.3% of deaths globally are attributable to asthma
02
The prevalence of hay fever (allergic rhinitis) in the United States is about 10%
03
Global allergic rhinitis prevalence is estimated at 10%–30% of the population
04
In the Global Allergy and Asthma European Network (GA2LEN) study, prevalence of allergic rhinitis ranged from 17.1% to 28.7% across surveyed European settings (study period reported as 2008–2009)
05
Globally, 235 million people are estimated to have asthma (estimate commonly reported in GBD-derived summaries)
06
Globally, 262 million people are estimated to have allergic rhinitis in a 2015 GBD-based estimate
07
In the European Union, an estimated 50 million people have allergic rhinitis (reported in EU public-health summaries referencing epidemiology evidence)
08
In the GBD 2019 study, allergic rhinitis accounted for 2.3 million disability-adjusted life-years (DALYs) in 2019 (GBD 2019 results reported in publication)
09
In GBD 2019, asthma accounted for 19.9 million DALYs globally in 2019 (GBD 2019 results reported in publication)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, allergy related conditions are affecting large populations worldwide, with asthma affecting an estimated 235 million people and allergic rhinitis estimated at 262 million, alongside substantial overall burden in 2019 reflected by 19.9 million DALYs for asthma and 2.3 million DALYs for allergic rhinitis.
02 · Category
Industry Trends5 stats
01
In the U.S., asthma prevalence was 8.6% among adults in 2023
02
In the U.S., 3.5 million people have asthma who are children
03
Component-resolved diagnostics uptake is increasing in allergy clinics because it can improve specificity of allergen sensitization interpretation
04
Allergen immunotherapy adoption in clinical practice is expanding, with increasing use of both subcutaneous and sublingual routes documented in guideline updates
05
Telehealth allergy/asthma follow-up expanded during and after COVID-19, with surveys documenting increased remote care use
Interpretation
Industry Trends Interpretation
As the U.S. adult asthma prevalence reached 8.6% in 2023, allergy clinics are increasingly adopting industry driven innovations such as rising component-resolved diagnostics uptake and expanded immunotherapy options to better target care.
03 · Category
Market Size7 stats
01
Global allergies market is expected to reach $40.9 billion in 2025
02
The global allergy immunology therapeutics market is forecast to grow at a CAGR of 5.7% from 2023 to 2030
03
The U.S. allergy testing market is projected to reach $1.8 billion by 2030
04
The global allergen immunotherapy market is expected to reach $19.4 billion by 2032
05
The global antihistamines market is projected to reach $43.2 billion by 2032
06
The global nasal sprays market is expected to reach $16.6 billion by 2030
07
The global inhalers market is projected to reach $36.6 billion by 2028
Interpretation
Market Size Interpretation
The market size for allergy products and services is set to expand significantly, with figures like the global allergies market expected to reach $40.9 billion in 2025 and the global antihistamines market projected to hit $43.2 billion by 2032, reflecting strong and sustained growth across the allergy category.
04 · Category
Diagnosis And Testing5 stats
01
Serum-specific IgE testing can detect sensitization to specific allergens within minutes to days, depending on lab workflow
02
Nasal provocation testing is used to confirm allergic rhinitis triggers in clinical research protocols
03
Fractional exhaled nitric oxide (FeNO) testing is used as a non-invasive marker of eosinophilic airway inflammation, aiding asthma management decisions
04
Eosinophil counts are used to guide biologic selection for severe asthma; baseline peripheral eosinophil thresholds are used for eligibility
05
Oral food challenges are the gold standard for diagnosing food allergy
Interpretation
Diagnosis And Testing Interpretation
Across Diagnosis And Testing, rapid serum-specific IgE tests and noninvasive markers like FeNO help pinpoint allergic sensitization and airway inflammation within days or less, while definitive confirmation often still relies on gold-standard approaches such as oral food challenges.
05 · Category
Economic Impact8 stats
01
Economic burden of allergic disorders is linked to comorbid asthma and chronic rhinitis, increasing total healthcare utilization
02
Anaphylaxis incidence and emergency utilization drive direct medical costs in emergency care settings
03
Globally, allergic rhinitis causes substantial indirect costs through lost productivity, with billions in annual economic burden reported in reviews
04
Hospitalizations for anaphylaxis are costly; one study estimated average U.S. inpatient cost per anaphylaxis admission at several thousand dollars
05
Epinephrine auto-injectors are a key cost driver in emergency readiness for severe allergy
06
Pharmacological management of allergic rhinitis can require ongoing medication use, with spending tracked in national health expenditure analyses
07
In the U.S., prescription medicines for asthma had a large share of outpatient pharmaceutical spending reported in national spending datasets
08
The indirect costs of allergies can include school absences and reduced work productivity in allergy populations, reported in health economic studies
Interpretation
Economic Impact Interpretation
The economic impact of allergies is escalating beyond direct treatment costs as anaphylaxis and allergic rhinitis spur costly emergency care and lost productivity, with U.S. inpatient costs for each anaphylaxis admission running into several thousand dollars and global allergic rhinitis reviews reporting billions in annual indirect economic burden.
More related reading
06 · Category
Treatment Outcomes9 stats
01
Biologics targeting IgE have demonstrated reductions in exacerbation rates in randomized controlled trials for allergic asthma
02
The anti–IL-5/IL-5R class of biologics has shown reductions in severe exacerbations in asthma patients with elevated eosinophils in pivotal trials
03
Dupilumab (anti–IL-4/IL-13) reduced annualized asthma exacerbation rates in clinical trials, demonstrating measurable outcome improvements
04
Omalizumab reduced asthma exacerbations in patients with severe allergic asthma in phase 3 trial data
05
Subcutaneous allergen immunotherapy can reduce medication use for allergic rhinitis over multi-year treatment courses
06
Sublingual immunotherapy has been shown to improve symptom scores in pollen allergy populations in randomized evidence reviews
07
Anti-IL-4Rα therapy (dupilumab) improved lung function (e.g., FEV1) in atopic dermatitis and asthma clinical trials, reflecting measurable treatment response endpoints
08
In food allergy studies, oral immunotherapy has increased the proportion of participants who could tolerate higher doses of allergen compared with placebo
09
In peanut allergy, omalizumab followed by oral immunotherapy increased the likelihood of achieving desensitization in randomized trials
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes in allergy, multiple biologic and immunotherapy approaches show measurable reductions or improvements, including lowered asthma exacerbations with IgE and IL-5 pathway agents and annualized exacerbation rate reductions with dupilumab, alongside oral immunotherapy gains such as more participants tolerating higher food allergen doses than placebo.
07 · Category
Healthcare Utilization2 stats
01
In the United States, asthma accounted for 260,000 hospitalizations in 2021 (CDC NHDS+NAMCS compilation reported in CDC asthma surveillance tables)
02
A U.S. study estimated 3,040,000 ED visits per year were related to allergic diseases (including asthma and anaphylaxis) across the analysis period
Interpretation
Healthcare Utilization Interpretation
In the United States, asthma alone led to 260,000 hospitalizations in 2021, and a separate U.S. analysis estimated 3,040,000 annual emergency department visits for allergic diseases, underscoring that allergy-related conditions drive substantial and ongoing healthcare utilization.
08 · Category
Clinical Burden5 stats
01
In the United States, food allergies affected 2.0% of adults (2018)
02
Approximately 7.1% of adults in the United States have allergic rhinitis (2019–2020 National Health Interview Survey estimate)
03
Anaphylaxis incidence in emergency department visits was estimated at 7.9 per 100,000 person-years in a U.S. study (2003–2012)
04
In a large U.S. claims study, 20%–30% of patients with allergic rhinitis had comorbid asthma (reported range across stratified cohorts)
05
In a systematic review and meta-analysis, comorbidity prevalence of asthma among patients with allergic rhinitis was 18% (pooled estimate reported)
Interpretation
Clinical Burden Interpretation
The clinical burden of allergy in the US is substantial, with allergic rhinitis affecting about 7.1% of adults and a notable 18% to 30% of these patients also living with asthma, highlighting how comorbidity likely drives additional severity and healthcare use.
09 · Category
Cost Analysis3 stats
01
Allergic rhinitis is responsible for substantial direct and indirect healthcare costs; a 2011–2018 evidence synthesis reported the global economic burden at €55.2 billion per year (median estimate range reported across included studies)
02
The U.S. Institute of Medicine estimated that food allergy costs were $24.8 billion per year (U.S., 2010)
03
In a U.S. payer database analysis, the median annual cost per patient with allergic rhinitis was $1,526(2018 dollars; study reports median)
Interpretation
Cost Analysis Interpretation
Cost analysis shows that allergy is not just a clinical burden but a major economic one, with global allergic rhinitis costing about €55.2 billion per year and U.S. studies estimating allergic rhinitis at a median $1,526 per patient annually and food allergy at $24.8 billion per year.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Allergy Statistics. Gitnux. https://gitnux.org/allergy-statistics
MLA
Christopher Morgan. "Allergy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/allergy-statistics.
Chicago
Christopher Morgan. 2026. "Allergy Statistics." Gitnux. https://gitnux.org/allergy-statistics.
Sources & references
53 datasets cited across this report · attribution is report-level
+28 additional datasets cited (not shown individually)